Neovasc Inc. (NVCN): Price and Financial Metrics

Neovasc Inc. (NVCN)

Today's Latest Price: $3.30 USD

0.06 (1.85%)

Updated Jun 5 4:00pm

Add NVCN to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 132 in Medical - Devices & Equipment

See all "A" rated Strong Buy stocks

NVCN Stock Summary

  • Equity multiplier, or assets relative to shareholders' equity, comes in at -0.92 for Neovasc Inc; that's greater than it is for merely 5.73% of US stocks.
  • As for revenue growth, note that NVCN's revenue has grown -78.93% over the past 12 months; that beats the revenue growth of merely 1.51% of US companies in our set.
  • Neovasc Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -75.63%, greater than the shareholder yield of only 5.29% of stocks in our set.
  • Stocks that are quantitatively similar to NVCN, based on their financial statements, market capitalization, and price volatility, are XLRN, SGMO, RMBS, MRUS, and STRO.
  • Visit NVCN's SEC page to see the company's official filings. To visit the company's web site, go to
NVCN Daily Price Range
NVCN 52-Week Price Range

NVCN Stock Price Chart More Charts

NVCN Price/Volume Stats

Current price $3.30 52-week high $8.65
Prev. close $3.24 52-week low $1.24
Day low $3.13 Volume 215,696
Day high $3.33 Avg. volume 309,216
50-day MA $2.40 Dividend yield N/A
200-day MA $2.96 Market Cap 38.96M

Neovasc Inc. (NVCN) Company Bio

Neovasc is a specialty medical device company that develops, manufactures and markets products for the cardiovascular marketplace. The Company also sells a line of biological tissue products that are used as components in third-party medical products including transcatheter heart valves. The company was founded in 2000 and is based in Richmond, Canada.

NVCN Latest News Stream

Event/TimeNews Detail
Loading, please wait...

NVCN Latest Social Stream

Loading social stream, please wait...

View Full NVCN Social Stream

Latest NVCN News From Around the Web

Below are the latest news stories about Neovasc Inc that investors may wish to consider to help them evaluate NVCN as an investment opportunity.

Neovasc Announces Closing of Final Convertible Debt Issuance for Gross Proceeds of US$5.0 Million

Following the earlier issuance to Strul of a convertible note in the principal amount of US$4 million and 2,573,959 warrants (the “Warrants”), the Company has raised aggregate gross proceeds of US$5 million (the “Offering”). Pursuant to the Offering the Company issued notes in the aggregate principal amount of US$5 million (the “2020 Notes”), convertible at $2.81525 per common share for 1,776,041 common shares, and 2,573,959 Warrants exercisable at $ 2.634 per Warrant share with a 4-year term.

Yahoo | June 4, 2020

Neovasc Reducer Spotlighted in Leading German Public Television Program

Elective Interventional Procedures Resume in Germany Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - June 3, 2020) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina, today announced that the Neovasc Reducer™ device ("Reducer") for the treatment of refractory angina was featured on the Hamburg-based German public television program NDR Visite. The ...

Yahoo | June 3, 2020

How Hedge Funds Traded Neovasc Inc. (NVCN) During The Crash

The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F […]

Yahoo | May 28, 2020

Neovasc Has Filed for CE Mark for Tiara TA Transapical Mitral Valve Replacement System

Less invasive approach provides hope for the millions of patients that suffer from leaky mitral valves Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - May 27, 2020) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina, today announced that the Company has filed for CE Mark for its Tiara TA Transapical ...

Yahoo | May 27, 2020

Neovasc Provides Corporate Update

After a marked slowdown that began in March, Reducer implant rates in Germany, where the company has a direct sales team and NUB Status 1 designation for reimbursement, are once again approaching pre-COVID-19 levels. As previously discussed, the company is aware of the backlog of potential Reducer patients related to COVID-19 and the reduction in elective procedures in select European markets and we look forward to continued acceleration. The National Institute for Health and Care Excellence (NICE) Interventional Procedures Programme in the U.K. has invited Neovasc to participate in guidance development for Reducer treatment of refractory angina.

Yahoo | May 26, 2020

Read More 'NVCN' Stories Here

NVCN Price Returns

1-mo 27.91%
3-mo 23.67%
6-mo 10.74%
1-year -32.35%
3-year -99.78%
5-year -99.95%
YTD -39.00%
2019 -9.83%
2018 -99.00%
2017 -65.32%
2016 -61.56%
2015 -34.02%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8029 seconds.